Matinas BioPharma (MTNB) Q4 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on lipid nanocrystal (LNC) platform, with lead candidate MAT2203 (oral amphotericin B) for invasive fungal infections, currently paused pending partnership or capital raise.

• 80% workforce reduction in late 2024, cost-cutting measures, and halted internal pipeline development to conserve cash.

• Ongoing efforts to secure a partner or sale for MAT2203; failure may result in company winddown or dissolution.

Financial highlights

• Net loss for 2025 was $10.3 million, down from $24.3 million in 2024.

• No revenue generated in 2025 or 2024; accumulated deficit reached $210.8 million as of December 31, 2025.

• Cash and cash equivalents at year-end 2025 were $4.0 million, not sufficient to fund operations beyond the next 12 months.

• Research and development expenses dropped sharply to $85,000 in 2025 from $11.4 million in 2024 due to program pause and workforce reduction.

• General and administrative expenses were $6.9 million in 2025, down from $8.7 million in 2024.

• No impairment charges in 2025; $4.4 million in impairment charges recorded in 2024 related to goodwill, IPR&D, and other assets.

Outlook and guidance

• Substantial doubt exists about ability to continue as a going concern without additional capital or a partnership.

• Expenses expected to remain low until additional funding or a partnership is secured; resumption of MAT2203 development would increase costs.

• No expectation of product revenue for several years, if ever.